September 24, 2021 10:37 AM EDT
R&D
Cell/Gene Tx

Mi­cro­cap gene ther­a­py play­er says three chil­dren suf­fered se­ri­ous side ef­fects in PhI/II study

Max Gelman

Senior Editor

A small biotech look­ing to de­vel­op a gene ther­a­py for a rare con­di­tion that can cause col­or or le­gal blind­ness ran in­to some sig­nif­i­cant safe­ty …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Up­dat­ed: Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

Gene edit­ing start­up Scribe Ther­a­peu­tics lets go of staff as it preps for the clin­ic

MaaT Phar­ma touts ‘un­prece­dent­ed’ Phase 3 ef­fi­ca­cy of graft-ver­sus-host dis­ease treat­ment

Astel­las stops de­vel­op­ing au­tol­o­gous cell ther­a­py us­ing tech from Xyphos buy­out

Re­silience cuts 120 em­ploy­ees at a for­mer blue­bird gene ther­a­py site

A service from the Financial Times